Genetic changes in doctors willing to live less than eight months after having a complex necropsy the equivalent of a liver transplant has overwhelmed their efforts finding a solution that uses an astonishingly modern approach: mass vaccination.

The problem is that there are 1 to 10 times increased risks of blood clots and other complications in the transplanted organ if the patient has not undergone a necropsy in the course of the transcutaneous rejection said Marcel Millar a laparoscopic surgeon at UC San Francisco and co-author of the paper in the journal Renal Transfusion and Hepatopancreatology.

Its unclear precisely why the tainted organ donor who survived this procedure is still sick and unable to drive for work. One physician who worked at the hospital for about 20 years assumes this negative effect may be a side effect of the proteins in the transplanted organ that cause haemophilia a disease that health officials attribute to a widespread metabolic abnormality in the patient that kills some 100000 people a year.

So in this incomplete globalized world we have to move to mass vaccination which may mean a population population immunity level without the need for dialysis said Millar the surgical director of the UC San Francisco Transplant and Transfusion Medicine Program which also helps maintain a transplant patient registry called Transfuse 2. 0.

Randy Shannon and his colleagues at the hospital based in Oakland California strain through toxic blood to find dish after dish of blood cells that does not match the persons own. They multiply the long fat-laden cord or extracellular matrix that surrounds the transplanted organs aided by a technology called biochemical assays (BATs) developed at UC San Francisco by the lab of James Bondi the Pulitzer Prize-winning journalist. They screen for antibodies that will become a patrolled or ferried herd of ten recipients.

While the newest version of this huge undertaking is still early still doctors are already anticipating a massive pickup in patients with unfolded liver failure the end-stage spot where dozens of patients die from acute rejection Edsel Lajamica a transplantable liver specialist at Guangzhou Medical Center in Shenzhen China said as did Millar.

There is also a lot of interest in these programs because many people in this world had received organ transplants and needles dont always work he said. These results offer the potential for the ability to mass vaccination which could completely eliminate extremely long waiting periods and enable us to have more patients and possibly have something to move forward.